AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

Bridgepoint slid on Friday after a group of 103 current and former employees and some related entities sold 14.7m shares in a placing. According to terms seen by Bloomberg, the shares were priced via ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...

AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...

The stock fell 15% after the consumer goods firm swung to a loss of £96m for the 12 months to the end of May, against a £62m ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...